Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
JJCR Pharmaceuticals Co.,Ltd. logo
4552TSE Prime

JCR Pharmaceuticals Co.,Ltd.

ＪＣＲファーマ Yahoo Finance

Recent & upcoming events

Jul 30
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 22
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
May 13
Earnings 2:00
FY earnings announcement (scheduled)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Oct 15
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
Dec 31
Est.
Earnings 1:00 approx.
Q2 earnings
Add to Google Calendar
2027
Mar 18
Est.
Earnings 2:00 approx.
Q3 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Jun 10
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar

KPI highlights

FY26
Revenue ¥40.32B YoY +21.9%
Operating income ¥555M margin 1.4%
Net income ¥2.18B YoY —
EPS ¥18 YoY —
P/E —
ROE 4.6% Equity ratio 43% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥45.70B +13.3%
Operating income ¥1.10B +98.2%
Net income ¥200M -90.8%
EPS ¥2 -90.8%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥10.81B¥13.46B¥9.45B¥9.15B——
Operating income ¥2.07B¥4.83B¥911M¥-277M——
Net income ¥1.61B¥3.65B¥-88M¥364M——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2021–2026）

事業法人 36.8%国内機関 16.3%未開示 43.3%202120222023202420252026
事業法人国内機関海外機関個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

株式会社メディパルホールディングス 23.8%株式会社メディパルホールディングス日本マスタートラスト信託銀行株式会社 7.6%日本マスタートラスト信託銀行株式会社（信託口）フューチャーブレーン株式会社 7.1%フューチャーブレーン株式会社野村信託銀行株式会社（Ａ信託口） 4.5%野村信託銀行株式会社（Ａ信託口）株式会社日本カストディ銀行（信託口） 4.2%株式会社日本カストディ銀行（信託口）キッセイ薬品工業株式会社 4%キッセイ薬品工業株式会社持田製薬株式会社 1.8%持田製薬株式会社202120222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
株式会社メディパルホールディングス 29,131,000 23.8% Yuho (EDINET)
日本マスタートラスト信託銀行株式会社（信託口） 9,273,000 7.6% Yuho (EDINET)
フューチャーブレーン株式会社 8,711,000 7.1% Yuho (EDINET)
野村信託銀行株式会社（A信託口） 5,498,000 4.5% Yuho (EDINET)
株式会社日本カストディ銀行（信託口） 5,169,000 4.2% Yuho (EDINET)
キッセイ薬品工業株式会社 4,918,000 4.0% Yuho (EDINET)
持田製薬株式会社 2,200,000 1.8% Yuho (EDINET)
ゴールドマン・サックス証券株式会社BNYM 1,527,000 1.2% Yuho (EDINET)
吉村 光司 1,500,000 1.2% Yuho (EDINET)
JCRファーマ従業員持株会 1,489,000 1.2% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

6/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 2.0%
✗ Positive operating cash flow ¥-135M
✓ ROA improved YoY -4.5% → 2.0%
✗ Operating CF exceeds net income (accrual quality) OCF ¥-135M / net income ¥2.18B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 44.8% → 42.9%
✓ Current ratio improved 1.16× → 1.16×
✓ No dilution (shares outstanding did not increase) 129,686,000 → 129,686,000
✓ Gross margin improved 65.7% → 74.9%
✓ Asset turnover improved 0.32× → 0.37×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 42.9%
Current ratio 1.2×
Years of positive operating CF 7 of last 10 yrs
Payout ratio 127%
Latest fiscal year result Profit (net income ¥2.18B)

Performance history

Last 10 years
0億円128億円255億円383億円511億円 FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue 181206232248301511343429331403
Operating income 23.637.849.732.482.719949.875.3-66.55.55
Ordinary income 25.338.450.732.984.920554.272.6-74.811.7
Net income 18.630.737.226.868.914537.755.1-47.621.8
Total assets 3643844254787389719491,0221,0491,092
Equity 276275309326386511524565474474

Indicators & cash flow

*Split-adjustedUnit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
EPS ¥4¥6¥8¥5¥56¥117¥30¥44¥-38¥18
ROE 6.9%11.3%13.0%8.6%19.8%32.9%7.4%10.3%-9.3%4.6%
Operating CF 26.531.339.149.310392.9-55.093.1-54.9-1.35
Investing CF -8.41-15.92.40-41.6-32.9-32.5-150-26.9-98.7-125
Financing CF 1.46-21.8-9.1720.583.0-21.819.5-20.397.4133
FCF 18.115.541.57.6670.560.4-20566.2-154-126

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data